paromomycin

Phase 3Small molecule

DDrugs for Neglected Diseases

paromomycin is one of 67 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous LeishmaniasisActive, not recruiting

Visceral LeishmaniasisActive, not recruiting

Pulmonary TuberculosisActive, not recruiting

Cutaneous LeishmaniasisPhase 3

Active, not recruiting

Visceral LeishmaniasisPhase 3

Active, not recruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

129 competitors in Pulmonary Tuberculosis

#DrugCompanyPhaseTrials

Mycobutin

Pfizer

Phase 3

1 2

Sirturo

WWim Janssens

Phase 3

8 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 5

Galzin

AAmerican Regent, Inc.

Phase 3

1 6

Nicotine Free Cigarettes

Pfizer

Phase 3

1 7

L-Arginine

Mario Negri Institute for Pharmacological Research

Phase 3

1 8

Merrem

BB. Braun Medical Inc.

Phase 2

1 9

Rifampicin

Boehringer Ingelheim

Phase 2

7 10

paromomycin

DDrugs for Neglected Diseases

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Adult

NCT06907498

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis3 trials

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Completed·FFundacion Nacional de Dermatologia·Phase 2/3·NCT03829917·120 enrolled

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

No longer available·UU.S. Army Medical Research and Development Command··NCT01641796

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT01790659·399 enrolled

Visceral Leishmaniasis3 trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Completed·DDrugs for Neglected Diseases·Phase 2·NCT05957978·52 enrolled

An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Completed·—·Phase 3·NCT00629031·329 enrolled

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Completed·DDrugs for Neglected Diseases·Phase 3·NCT03129646·439 enrolled

Adult1 trial

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

Recruiting·SSheba Medical Center·N/A·NCT06907498·60 enrolled

Treatment1 trial

Short Course Regimens for Treatment of PKDL (Sudan)

Unknown status·DDrugs for Neglected Diseases·Phase 2·NCT03399955·110 enrolled

Pulmonary Tuberculosis1 trial

Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004444·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for paromomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — paromomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for paromomycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Drugs for Neglected Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDrugs for Neglected Diseases

paromomycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cutaneous Leishmaniasis3 trials

Visceral Leishmaniasis3 trials

Adult1 trial

Treatment1 trial

Pulmonary Tuberculosis1 trial

References

Drug Info

Quick Facts

Related News